Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business

NexMed Receives Cash Infusion of $750,000


Print article Print article
Refer this article Refer to a friend
© Business Wire 2009
2009-11-11 14:45:03 -

NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the NexACT ® drug delivery technology, today announced that it raised $750,000 in gross proceeds from the issuance of new convertible notes due December 31, 2011 (the “Notes”), which are secured by a mortgage on NexMed’s facility in East Windsor, New Jersey.

The Notes were purchased by two investors,

including The Tail Wind Fund Ltd., a long term investor in NexMed.

The Notes are convertible into shares of NexMed common stock at $2 per share with a coupon rate of 7% per annum. The shares underlying the Notes will not be registered with the Securities and Exchange Commission.

About NexMed


NexMed’s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a P 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com : .



NexMed, Inc.Mark Westgate, 609-371-8123, ext: 159CFO mwestgate@nexmed.com : mailto:mwestgate@nexmed.com orInvestor
Relations:Rx Communications Group, LLCPaula Schwartz,

917-322-2216 pschwartz@rxir.com : mailto:pschwartz@rxir.com


Disclaimer: (c) 2009 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Terms & Conditions | Privacy | About us | Contact PR-inside.com